close

Fenwick Represents Dermira in Pending $1.1 Billion Acquisition by Lilly

January 10, 2020

Eget nulla facilisi etiam dignissim diam quis enim. In ornare quam viverra orci. Ultrices eros in cursus turpis massa tincidunt dui ut. Vitae auctor eu augue ut lectus. Eros in cursus turpis massa tincidunt dui ut ornare. Pharetra et ultrices neque ornare aenean euismod elementum nisi. Luctus venenatis lectus magna fringilla urna porttitor rhoncus dolor purus. Commodo odio aenean sed adipiscing diam donec adipiscing. Semper quis lectus nulla at. Sed risus ultricies tristique nulla aliquet enim tortor at. Dolor purus non enim praesent elementum facilisis leo vel fringilla. Vitae sapien pellentesque habitant morbi tristique senectus et netus et. Ac placerat vestibulum lectus mauris ultrices eros in cursus. Sit amet commodo nulla facilisi nullam vehicula ipsum a. Facilisis magna etiam tempor orci eu. Urna id volutpat lacus laoreet non curabitur gravida arcu ac. Sed risus pretium quam vulputate dignissim suspendisse in est.

Fenwick & West is representing Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to developing new therapies for chronic skin conditions, in its definitive agreement to be acquired by Eli Lilly and Company (NYSE: LLY) for $18.75 per share, or approximately $1.1 billion, in an all-cash transaction. The transaction is expected to close by the end of the first quarter of 2020, subject to customary closing conditions. More information about the acquisition can be obtained from the company announcement​.

The transaction team includes corporate partners Doug Cogen and David Michaels, and associates Katherine Duncan, Jennifer Hitchcock, Janiece Jenkins, Grace Strickland, Victoria Lupu and Carson Jackson; executive compensation and employee benefits partners Matthew Cantor, Scott Spector and Elizabeth Gartland, and counsels Nicholas Frey and Laura McIntyre; technology transactions partner Stefano Quintini and associates Sophia Chen and Sang Kwon; intellectual property partner Daniel Becker; antitrust and trade regulation partner Mark Ostrau; and tax partner William Skinner and associate Ora Grinberg.

Accumsan sit amet nulla facilisi. Nec feugiat nisl pretium fusce id velit ut tortor. Euismod nisi porta lorem mollis aliquam ut porttitor leo a. Faucibus vitae aliquet nec ullamcorper sit amet risus. Purus semper eget duis at. Convallis convallis tellus id interdum velit laoreet. Hendrerit dolor magna eget est lorem ipsum dolor sit. Porttitor leo a diam sollicitudin tempor id. Sit amet consectetur adipiscing elit ut aliquam purus sit amet. Morbi quis commodo odio aenean sed. Elementum facilisis leo vel fringilla est ullamcorper. Tristique senectus et netus et malesuada fames. Diam in arcu cursus euismod quis viverra. Viverra nam libero justo laoreet sit amet. Elementum integer enim neque volutpat ac tincidunt vitae semper quis. Feugiat nisl pretium fusce id. Id diam vel quam elementum pulvinar etiam. Nec nam aliquam sem et tortor consequat id. Mattis aliquam faucibus purus in massa. Sed viverra tellus in hac habitasse platea.​​